Lobe Sciences Stock Price, News & Analysis

Lobe Sciences (LOBEF) has provided a comprehensive corporate update detailing several key transactions and operational developments. The company issued multiple convertible notes throughout 2024, including C$678,450 in March, C$1,462,716 in May, and US$250,000 in December, all bearing 10% annual interest.

The company settled various debts through share issuances, including 16.4M shares to Clearway Global, 10.8M shares to former directors and officers, and implemented a director compensation agreement involving 7M shares per director. Additionally, 3.5M restricted share units were issued to a subsidiary officer.

On the operational front, Lobe Sciences highlighted progress with Conjugated Psilocin™, securing two US patents and filing international applications. The company published Phase 1 clinical trial results and received pre-IND feedback from the FDA, marking significant steps toward human clinical trials.

Lobe Sciences and its subsidiary Alera Pharma have received a second patent allowance for Conjugated Psilocin™ from the U.S. Patent Office. The patent covers compositions comprising psilocin mucate salt or conjugate and their production methods. Conjugated Psilocin™ is a stable, highly bioavailable analogue of psilocin, the active metabolite of psilocybin, with potential applications in treating neurological disorders, particularly chronic cluster headache. The intellectual property rights will be assigned to Alera Pharma, which is currently pursuing fundraising activities for drug development.

Lobe Sciences (CSE: LOBE, OTCQB: LOBEF), a biopharmaceutical company, has announced the appointment of Enclave Capital and Peak Asset Management to initiate fundraising for the development of their patented pharmaceutical candidate, Conjugated Psilocin™. This move follows the company's recent establishment of Alera Pharma, Inc. as an operating entity for drug development.

Dr. Fred Sancilio, Chairman and CEO of Lobe Sciences, emphasized the significance of this appointment in advancing their development plans, particularly in light of the recently issued new chemical entity patent for Conjugated Psilocin™. The company aims to progress this drug candidate through the US FDA NDA development process efficiently, focusing on treating diseases with significant unmet medical needs.

Lobe Sciences and Alera Pharma announce the issuance of U.S. Patent number 12,102,616 for Conjugated Psilocin™. The patent, titled 'Psilocin Mucate', covers compositions of matter, methods of use, and production for psilocin mucate. It will be valid until July 2043, subject to maintenance fees. Lobe Sciences will assign the intellectual property rights to Alera Pharma, its newly established wholly-owned subsidiary.

Conjugated Psilocin™ is a novel, oral, stable analogue of psilocin, addressing the instability issues of psilocin and poor bioavailability of psilocybin. The companies aim to develop it as a prescription medication for various neurological disorders, with a primary focus on Chronic Cluster Headache.

Lobe Sciences (CSE: LOBE, OTCQB: LOBEF) has announced the creation of a wholly owned U.S. subsidiary, Alera Pharma, Inc. This new entity will focus on neurology and be assigned the intellectual property rights for Lobe's lead compound, Psilocin Mucate. Key appointments include:

- Rick Goulburn as CEO of Alera Pharma
- Dr. Frederick D. Sancilio as Chairman of Alera Pharma's Board
- Dr. Harry Jacobson, Wesley Ramjeet, and Rick Goulburn as Board Members
- Ilan Hayman joining Alera's executive management team

Lobe Sciences Australia Pty will become a subsidiary of Alera Pharma. The company also received a Notice of Allowance from the US PTO for its Patent Application Serial No. 18/411,576. This restructuring aims to simplify Lobe Sciences' operations into three entities: Lobe Sciences , Alera Pharma, and Altemia,

Lobe Sciences (CSE: LOBE, OTCQB: LOBEF), a biopharmaceutical company, has announced significant changes to its leadership structure. At the company's annual general meeting, shareholders elected a new Board of Directors comprising Dr. Frederick D. Sancilio, Dr. Harry Jacobson, and Mr. Wesley Ramjeet. Following this, the Board appointed Dr. Sancilio as Chairman and CEO, replacing the departing CEO Philip Young and COO Baxter Phillips III.

The Board also expanded with the addition of Mr. Rick Goulburn as its fourth member, expected to take on a leadership role in pursuing the company's strategic goals. Additionally, Mr. Jeremy Wright joined as a Board and Executive Advisor to provide guidance on strategic and administrative matters. These changes mark a significant shift in Lobe Sciences' leadership as it continues its focus on developing medicines for diseases with unmet medical needs.

Lobe Sciences, a biopharmaceutical company (OTCQB: LOBEF), announced its strategic efforts to enhance shareholder value, including up-listing to the Australian Securities Exchange or the New York Stock Exchange.

The company secured a $500,000 convertible note to improve its balance sheet, reducing short-term debt and preparing for long-term funding. The note is provided by Clearway Global, , and Quality Chemical Laboratories, Inc.

Lobe also plans to out-license its proprietary assets, especially L-130 and Altemia, and aims to communicate its significant scientific achievements through a series of market updates. The Annual General Meeting is scheduled for 22 July 2024.

Lobe Sciences (OTCQB: LOBEF, CSE: LOBE), a biopharmaceutical firm specializing in transformative medicines for rare diseases, has appointed Wesley Ramjeet to its Board of Directors. Ramjeet, CEO and Founder of PPMT Strategic Group, brings over two decades of strategic financial expertise, with notable achievements in acquisitions, IPOs, and growth initiatives across various industries. His leadership has driven significant growth and successful exits, including a 30x increase for MD Logic Wellness and a notable turnaround for a medical device company. CEO Philip J Young highlighted Ramjeet's strategic insights as key for Lobe's mission to advance innovative treatments for neurological disorders.

Ramjeet has also made significant contributions to the nonprofit sector, including founding Lions Unleashed and serving on the Board of Trustees for the Universal Hip Hop Museum. He is a CPA and holds a degree in Accounting from St. John’s University.

Lobe Sciences announced that Frederick D. Sancilio Ph.D. is joining its Board of Directors. Dr. Sancilio brings over 40 years of experience in pharmaceutical sciences, founding multiple successful companies, including aaiPharma. His expertise is expected to boost Lobe's efforts in developing treatments for rare diseases and mental health conditions. The company aims to leverage his experience to advance its L-130 oral psilocin program and expand the reach of Altemia, a medical food for Sickle Cell Disease. Dr. Sancilio's previous roles include significant contributions to drug development and FDA approvals.